查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1886608

微針流感疫苗市場－全球產業規模、佔有率、趨勢、機會和預測，依產品類型、疫苗類型、地區和競爭格局分類，2020-2030年預測

Microneedle Flu Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Vaccine Type, By Region, By Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球微針流感疫苗市場規模為11.8億美元，預計2030年將以5.96%的複合年成長率成長至16.7億美元。全球微針流感疫苗是一種創新的給藥系統，它利用通常整合在貼片中的微型針頭，將流感疫苗注射到皮膚表層，為傳統的肌肉注射提供了一種創傷較小的替代方案。該市場的成長主要受人們對無痛且可自行接種疫苗方式的需求不斷成長的推動，旨在減少針頭恐懼症並提高全球患者的依從性。

市場概覽
預測期 2026-2030
市場規模：2024年 11.8億美元
市場規模：2030年 16.7億美元
複合年成長率：2025-2030年 5.96%
成長最快的細分市場 實心微針
最大的市場 北美洲

主要市場促進因素

全球微針流感疫苗市場主要受以下因素影響：消費者對無痛、可自行接種疫苗的需求不斷成長，以及微針技術的持續進步。人們希望以更微創的方式接種疫苗，這是推動市場發展的重要因素，有助於解決普遍存在的針頭恐懼症，提高患者依從性，而這些因素歷來是疫苗接種的障礙。

主要市場挑戰

新型藥物遞送系統複雜而嚴格的法規核准流程，對全球微針流感疫苗市場的擴張構成了重大障礙。作為兼具醫療器材和生物製劑特性的產品，微針疫苗必須滿足廣泛而嚴格的臨床試驗要求。

主要市場趨勢

可溶解微針技術的出現標誌著疫苗遞送領域的一項顯著進步，它避免了尖銳生物危害性廢棄物的產生，從而提高了患者的舒適度和安全性。這些基於可生物分解聚合物的貼片可在皮膚內溶解，實現精準且持續的抗原釋放，有助於提高疫苗效力，並有可能降低疫苗劑量。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球微針流感疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型（實心微針、空心微針）
    • 依疫苗類型（三價流感疫苗、四價流感疫苗）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美微針流感疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲微針流感疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區微針流感疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲微針流感疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲微針流感疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球微針流感疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Debiotech SA
  • NanoPass Technologies Limited
  • Becton, Dickinson and Company
  • FluGen, Inc.
  • CosMED Pharmaceuticals Co., Ltd.
  • Microdermics Inc.
  • TSRL Inc.
  • Vaxess Technologies Inc.
  • Pfizer, Inc.
  • Merck & Co., Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22209

The Global Microneedle Flu Vaccine Market, valued at USD 1.18 Billion in 2024, is projected to experience a CAGR of 5.96% to reach USD 1.67 Billion by 2030. The global microneedle flu vaccine is an innovative delivery system utilizing microscopic needles, typically integrated into a patch, to administer the influenza vaccine into the superficial layers of the skin, offering a less invasive alternative to traditional intramuscular injections. This market's growth is primarily driven by the increasing demand for painless and self-administered vaccination methods, aiming to reduce needle phobia and enhance patient compliance globally.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.18 Billion
Market Size 2030USD 1.67 Billion
CAGR 2025-20305.96%
Fastest Growing SegmentSolid Microneedle
Largest MarketNorth America

Key Market Drivers

The global microneedle flu vaccine market is primarily influenced by the rising demand for painless and self-administered vaccination methods and continuous advancements in microneedle technology. The desire for less invasive vaccine delivery is a significant driver, addressing widespread needle phobia and improving patient compliance, which traditionally pose barriers to vaccination uptake. For instance, according to a study published in the *Journal of Multidisciplinary Healthcare*, in May 2024, "Prevalence, factors associated and management of needle phobia among the general population in Saudi Arabia and Egypt", approximately 36.5% of adult participants reported experiencing needle phobia, highlighting a substantial population that could benefit from alternative administration routes.

Key Market Challenges

The complex and stringent regulatory approval process for novel drug delivery systems presents a significant obstacle to the expansion of the global microneedle flu vaccine market. As products combining both a medical device and a biologic, microneedle vaccines are subject to extensive and rigorous requirements for clinical trials. These trials must rigorously demonstrate the safety, efficacy, and consistent manufacturing scalability of the integrated system.

Key Market Trends

The shift towards dissolvable microneedle technologies marks a notable advancement in vaccine delivery, offering enhanced patient comfort and safety by eliminating sharp biohazardous waste. These biodegradable polymer-based patches dissolve within the skin, facilitating precise and sustained antigen release, which can improve vaccine efficacy and potentially allow for reduced dosage requirements. This trend underscores the industry's commitment to innovation in materials science for medical applications.

Key Market Players

  • Debiotech S.A.
  • NanoPass Technologies Limited
  • Becton, Dickinson and Company
  • FluGen, Inc.
  • CosMED Pharmaceuticals Co., Ltd.
  • Microdermics Inc.
  • TSRL Inc.
  • Vaxess Technologies Inc.
  • Pfizer, Inc.
  • Merck & Co., Inc.

Report Scope:

In this report, the Global Microneedle Flu Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Microneedle Flu Vaccine Market, By Product Type:

  • Solid Microneedle
  • Hollow Microneedle

Microneedle Flu Vaccine Market, By Vaccine Type:

  • Trivalent Flu Vaccine
  • Quadrivalent Flu Vaccine

Microneedle Flu Vaccine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Microneedle Flu Vaccine Market.

Available Customizations:

Global Microneedle Flu Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Microneedle Flu Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Solid Microneedle, Hollow Microneedle)
    • 5.2.2. By Vaccine Type (Trivalent Flu Vaccine, Quadrivalent Flu Vaccine)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Microneedle Flu Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Vaccine Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Microneedle Flu Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Vaccine Type
    • 6.3.2. Canada Microneedle Flu Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Vaccine Type
    • 6.3.3. Mexico Microneedle Flu Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Vaccine Type

7. Europe Microneedle Flu Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Vaccine Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Microneedle Flu Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Vaccine Type
    • 7.3.2. France Microneedle Flu Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Vaccine Type
    • 7.3.3. United Kingdom Microneedle Flu Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Vaccine Type
    • 7.3.4. Italy Microneedle Flu Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Vaccine Type
    • 7.3.5. Spain Microneedle Flu Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Vaccine Type

8. Asia Pacific Microneedle Flu Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Vaccine Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Microneedle Flu Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Vaccine Type
    • 8.3.2. India Microneedle Flu Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Vaccine Type
    • 8.3.3. Japan Microneedle Flu Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Vaccine Type
    • 8.3.4. South Korea Microneedle Flu Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Vaccine Type
    • 8.3.5. Australia Microneedle Flu Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Vaccine Type

9. Middle East & Africa Microneedle Flu Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Vaccine Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Microneedle Flu Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Vaccine Type
    • 9.3.2. UAE Microneedle Flu Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Vaccine Type
    • 9.3.3. South Africa Microneedle Flu Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Vaccine Type

10. South America Microneedle Flu Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Vaccine Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Microneedle Flu Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Vaccine Type
    • 10.3.2. Colombia Microneedle Flu Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Vaccine Type
    • 10.3.3. Argentina Microneedle Flu Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Vaccine Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Microneedle Flu Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Debiotech S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. NanoPass Technologies Limited
  • 15.3. Becton, Dickinson and Company
  • 15.4. FluGen, Inc.
  • 15.5. CosMED Pharmaceuticals Co., Ltd.
  • 15.6. Microdermics Inc.
  • 15.7. TSRL Inc.
  • 15.8. Vaxess Technologies Inc.
  • 15.9. Pfizer, Inc.
  • 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer